Sales and earnings (Q2 2021)

Net revenue
160 221 KSEK (+400%)
44 031 KSEK (27.5%)

Financial reports

Half Year Report
Q2 2021
Interim Report
Q1 2021
Year End Report
Q4 2021
Interim Report
Q3 2020


October 28th
Interim Report Q3 2021
February 17th
Year-end report 2021
April 28th
Interim Report Q1 2022
July 28th
Half Year Report 2022
September 14th
ABG Investor Day 2022


Dr. Pol Signs Licensing Agreement with Swedencare
8 SEP 2021 9.30
Swedencare has completed the American acquisition
1 JULY 2021 5:15
Swedencare completes directed new share issue
28 JUNE 2021 7:45

Latest presentations

ABGSC Investor Day
Swedencare acquires US-based Vetio
1 JULY 2021
SEB Growth Market 2021
19 MAY 2021
  • Investor contact

    If you have any questions or concerns- please do not hesitate to contact us!

  • Presentation of Q2

    “We have made many good acquisitions over the years, but Vetio is the most transformative, not only due to size but since we now possess a width and capacity that not many in the animal health industry do. This means that we will get opportunities to completely new types of business deals and give us a rather unique position in the market.” – Håkan Lagerberg, CEO

    CEO Håkan Lagerberg